HOUSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the first quarter ended March 31, 2026 and provided an operational and business update. First Quarter 2026 Financial Summary Total revenues of approximately $1.3 million (including approximately $1,224,000 of product revenues) increased 169% over the 2025 first quarter and 20% over last year's fourth quarter Aurix branded product revenues were up over 30% sequentially versus 2025 fourth quarter Net operating loss of approximately $446,000 compared to 2025's first quarter net operating loss of approximately $745,000 Operational and Business Update Witnessing robust demand for the Aurix product in private physician office settings Market responding favorably to continued improvement in Medicare related reimbursement for Aurix and a vastly changed overall reimbursement landscape Entered into a Loan and Security Agreement with initial fundings of $1.0 million designed to provide working capital as the company invests in growth and moves closer to breakeven operations “Just over one year ago, Nuo issued our most recent press release and announced the exclusive private label distribution agreement with Smith+Nephew.